-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JpFd5J0JuB9rQnF6kzZQ2gsmsi48vlTDMEpLWpUJ6HiVJNiG33LkI4/9gnqxEaEJ jacYvIobKh7UC5LPXhtatg== 0000912057-00-018591.txt : 20000419 0000912057-00-018591.hdr.sgml : 20000419 ACCESSION NUMBER: 0000912057-00-018591 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20000418 ITEM INFORMATION: FILED AS OF DATE: 20000418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENOME THERAPEUTICS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-10824 FILM NUMBER: 604022 BUSINESS ADDRESS: STREET 1: 1OO BEAVER ST CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6178935007 MAIL ADDRESS: STREET 1: 100 BEAVER STREET CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 8-K 1 FORM 8-K - -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 -------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): APRIL 18, 2000 -------------------- GENOME THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) MASSACHUSETTS 0-10824 04-2297484 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorporation) Identification Number) 100 BEAVER STREET WALTHAM, MASSACHUSETTS 02453 (Address, of principal executive offices, including zip code) (781) 398-2300 (Registrant's Telephone number including area code) -------------------- - -------------------------------------------------------------------------------- Item 5. OTHER EVENTS On April 13, 2000, Genome Therapeutics Corp. issued a press release announcing that it would not proceed with its follow-on public offering and that it would file an amendment to the registration statement that it filed with the Securities and Exchange Commission on March 16, 2000 to convert it to a shelf registration statement. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1. -2- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENOME THERAPEUTICS CORP. By /s/ Robert J. Hennessey --------------------------------- Title: Chairman of the Board and Chief Executive Officer Date: April 18, 2000 -3- EXHIBIT INDEX 99.1 Press Release dated April 13, 2000 -4- EX-99 2 EXHIBIT 99 Contacts: Christopher Taylor Douglas MacDougall Director of Investor Relations Vice President Genome Therapeutics Corp. Feinstein Kean Healthcare 781.398.2466 617.577.8110 FOR IMMEDIATE RELEASE GENOME THERAPEUTICS CANCELS FOLLOW-ON PUBLIC OFFERING WALTHAM, MASS., APRIL 13, 2000 -- Genome Therapeutics Corp. (Nasdaq: GENE) announced that in light of recent market volatility and current market conditions, the Company would not proceed with its proposed follow-on public offering at this time. Genome Therapeutics will file an amendment to the registration statement that it filed with the Securities and Exchange Commission on March 16, 2000 to convert it to a shelf registration statement. Genome Therapeutics (WWW.GENOMECORP.COM) is a leader in the commercialization of genomics-based drug discovery. The Company's gene discovery strategy is to identify and characterize human genes associated with major diseases and elucidate microbial genes as novel drug targets against many serious infectious organisms. Together with its strategic partners, including Schering-Plough, AstraZeneca, Wyeth-Ayerst and bioMerieux, Genome Therapeutics is using genomic information to develop a new generation of genomics-based pharmaceutical, vaccine and diagnostic products. # # # -----END PRIVACY-ENHANCED MESSAGE-----